View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 26, 2022

Quantum Leap, Ambrx to include ADC in Phase II breast cancer trial

Ambrx expects to commence subject enrolment in the ARX788 arms in May this year.

Quantum Leap Healthcare Collaborative and Ambrx Biopharma have selected the latter’s antibody drug conjugate (ADC), ARX788, for a new investigational treatment arm in the Phase II I-SPY 2.2 TRIAL to treat HER2-positive breast cancer in the neoadjuvant setting. 

An anti-HER2 antibody drug conjugate (ADC), ARX788 is being analysed widely in breast cancer, gastric / gastroesophageal junction (GEJ) cancer and various other solid tumours. 

The adaptive trial is sponsored by Quantum Leap and assesses developing targeted agents to combine them with less toxic chemotherapeutic regimens or to completely replace cytotoxic chemotherapy. The company expects to commence subject enrolment in the ARX788 arms in May this year.

In the trial, ARX788 will be assessed as a single agent and along with the programmed cell death protein 1 (PD-1) targeting checkpoint inhibitor, cemiplimab, in subjects with HER2-positive early-stage breast cancer in the neoadjuvant setting. 

I-SPY 2.2 follows the I-SPY 2 TRIAL, designed to quickly analyse encouraging experimental therapies and detect the most effective ones in specific patient subgroups depending on molecular characteristics.

Ambrx Biopharma board chairman president and CEO Feng Tian said: “I am thrilled that Quantum Leap has selected Ambrx’s antibody drug conjugate, ARX788, to be evaluated in the I-SPY 2.2 TRIAL. 

“We are encouraged by the favourable anti-tumour activity and safety profile of ARX788 for the treatment of early-stage breast cancer. 

“It may provide a less toxic treatment option for patients through the precision conjugation of cytotoxic payloads targeting HER2 receptors.”

In April last year, Quantum Leap concluded subject enrolment in the icatibant arm of the I-SPY COVID Trial analysing various agents to treat critically ill patients.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU